AbbVie expects Botox market share to stay strong despite newer rivals
AbbVie expects its share of Botox in the aesthetics market to remain strong in the fourth quarter, despite recent launches of newer, longer-acting products by rival companies, the company's executi...
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note
The latest trading day saw AbbVie (ABBV) settling at $162.31, representing a +0.55% change from its previous close.
3 Simple Tricks That Every Investor Should Use (but Most Don't)
There's no rule that mandates betting on only one company in a sector. It's valuable to learn about the top people involved in a business.
AbbVie (ABBV) Now Trades Above Golden Cross: Time to Buy?
AbbVie Inc. (ABBV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ABBV's 50-day simple moving average crossed above its 2...
5 Dividend Aristocrats Primed For a Big 2024
The company develops and markets drugs in areas such as: Immunology Virology Renal disease Dyslipidemia Neuroscience One of the biggest concerns with AbbVie is what might eventually happen with the...
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
AbbVie is a Dividend King that should soon return to growth. Bristol Myers Squibb boasts an impressive streak of dividend hikes and a promising pipeline.
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie: Still Expensive Despite The Great M&A Acumen
ABBV's Humira erosion has been well balanced by the robust growth reported by Skyrizi and Rinvoq, implying its ability to maintain a stable top/ bottom line performance ahead. The management has al...
AbbVie shares higher following ‘overdone' reaction to CVS move to replace top-selling arthritis drug
Abbvie Inc (NYSE:ABBV) shares recovered in the early afternoon Thursday after dipping 3% in after hours trade the evening prior on the news that CVS Health Corp (NYSE:CVS) announced it will remove ...
Abbvie shares down as CVS moves to replace top selling arthritis drug with cheaper alternatives
Abbvie Inc (NYSE:ABBV) shares fell after hours on Wednesday after CVS Health Corp announced it will remove Humira, a leading rheumatoid arthritis medication, from some preferred drug lists for reim...
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
AbbVie (ABBV) closed the most recent trading day at $160.46, moving +0.4% from the previous trading session.
Abbvie shares tumble after CVS drops Humira in favor of biosimilars
CNBC's Bertha Coombs joins 'Fast Money' to talk Abbvie's stock sliding in extended trading after CVS announced it is dropping coverage of Humira.
CVS will remove AbbVie's Humira from some drug reimbursement lists in April
CVS Health said on Wednesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will recommend biosi...
7 Dividend Aristocrats With Boatloads of Passive Income Potential
The current market is characterized by price volatility and return uncertainty. However, seven companies span across various sectors—consumer staples, financial, healthcare, energy, industrials and...
3 Biotech Stocks Set for Breakthroughs in 2024
As we break into the new year, investors are on the hunt for the best biotech stocks to buy. Indeed, 2024 could witness groundbreaking advancements in technology and science.
Related Companies